These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38908756)

  • 1. Auto-loaded TRAIL-exosomes derived from induced neural stem cells for brain cancer therapy.
    Zhang X; Taylor H; Valdivia A; Dasari R; Buckley A; Bonacquisti E; Nguyen J; Kanchi K; Corcoran DL; Herring LE; Steindler DA; Baldwin A; Hingtgen S; Satterlee AB
    J Control Release; 2024 Aug; 372():433-445. PubMed ID: 38908756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Auto-loaded TRAIL-exosomes derived from induced neural stem cells for brain cancer therapy.
    Zhang X; Taylor H; Valdivia A; Dasari R; Buckley A; Bonacquisti E; Nguyen J; Kanchi K; Corcoran DL; Herring LE; Steindler DA; Baldwin A; Hingtgen S; Satterlee AB
    bioRxiv; 2024 May; ():. PubMed ID: 38854085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-homing cytotoxic human induced neural stem cells for cancer therapy.
    Bagó JR; Okolie O; Dumitru R; Ewend MG; Parker JS; Werff RV; Underhill TM; Schmid RS; Miller CR; Hingtgen SD
    Sci Transl Med; 2017 Feb; 9(375):. PubMed ID: 28148846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma.
    Bagó JR; Alfonso-Pecchio A; Okolie O; Dumitru R; Rinkenbaugh A; Baldwin AS; Miller CR; Magness ST; Hingtgen SD
    Nat Commun; 2016 Feb; 7():10593. PubMed ID: 26830441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model.
    Shamili FH; Bayegi HR; Salmasi Z; Sadri K; Mahmoudi M; Kalantari M; Ramezani M; Abnous K
    Int J Pharm; 2018 Oct; 549(1-2):218-229. PubMed ID: 30075248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and Profiling of Tumor-Homing Induced Neural Stem Cells from the Skin of Cancer Patients.
    Buckley A; Hagler SB; Lettry V; Bagó JR; Maingi SM; Khagi S; Ewend MG; Miller CR; Hingtgen SD
    Mol Ther; 2020 Jul; 28(7):1614-1627. PubMed ID: 32402245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumoricidal stem cell therapy enables killing in novel hybrid models of heterogeneous glioblastoma.
    Satterlee AB; Dunn DE; Lo DC; Khagi S; Hingtgen S
    Neuro Oncol; 2019 Dec; 21(12):1552-1564. PubMed ID: 31420675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized-induced neural stem cell therapy: Generation, transplant, and safety in a large animal model.
    Bomba HN; Sheets KT; Valdivia A; Khagi S; Ruterbories L; Mariani CL; Borst LB; Tokarz DA; Hingtgen SD
    Bioeng Transl Med; 2021 Jan; 6(1):e10171. PubMed ID: 33532581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corrigendum to "Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model" [International Journal of Pharmaceutics 549 (2018) 218-229].
    Shamili FH; Bayegi HR; Salmasi Z; Sadri K; Mahmoudi M; Kalantari M; Ramezani M; Abnous K
    Int J Pharm; 2019 Mar; 558():441. PubMed ID: 30765106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells.
    Zhu L; Oh JM; Gangadaran P; Kalimuthu S; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
    Front Immunol; 2018; 9():824. PubMed ID: 29740437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of FLOSEAL® as a scaffold and its impact on induced neural stem cell phenotype, persistence, and efficacy.
    Bomba HN; Carey-Ewend A; Sheets KT; Valdivia A; Goetz M; Findlay IA; Mercer-Smith A; Kass LE; Khagi S; Hingtgen SD
    Bioeng Transl Med; 2022 May; 7(2):e10283. PubMed ID: 35600639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle engineered TRAIL-overexpressing adipose-derived stem cells target and eradicate glioblastoma via intracranial delivery.
    Jiang X; Fitch S; Wang C; Wilson C; Li J; Grant GA; Yang F
    Proc Natl Acad Sci U S A; 2016 Nov; 113(48):13857-13862. PubMed ID: 27849590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering Exosomes Endowed with Targeted Delivery of Triptolide for Malignant Melanoma Therapy.
    Jiang L; Gu Y; Du Y; Tang X; Wu X; Liu J
    ACS Appl Mater Interfaces; 2021 Sep; 13(36):42411-42428. PubMed ID: 34464081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells.
    Bagci-Onder T; Du W; Figueiredo JL; Martinez-Quintanilla J; Shah K
    Brain; 2015 Jun; 138(Pt 6):1710-21. PubMed ID: 25910782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy.
    Teng J; Hejazi S; Badr CE; Tannous BA
    Stem Cells; 2014 Aug; 32(8):2021-32. PubMed ID: 24801379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of composite scaffold degradation rate on neural stem cell persistence in the glioblastoma surgical resection cavity.
    Moore KM; Graham-Gurysh EG; Bomba HN; Murthy AB; Bachelder EM; Hingtgen SD; Ainslie KM
    Mater Sci Eng C Mater Biol Appl; 2020 Jun; 111():110846. PubMed ID: 32279815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts.
    Balyasnikova IV; Ferguson SD; Han Y; Liu F; Lesniak MS
    Cancer Lett; 2011 Nov; 310(2):148-59. PubMed ID: 21802840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
    Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
    Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma.
    Crommentuijn MH; Maguire CA; Niers JM; Vandertop WP; Badr CE; Würdinger T; Tannous BA
    Mol Oncol; 2016 Apr; 10(4):625-34. PubMed ID: 26708508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
    Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
    Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.